Cheng Yi Pharma(SH:603811)2023-04-25 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥147,830,388.05, representing a decrease of 7.40% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥39,749,555.71, an increase of 37.44% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥38,805,216.40, up by 25.50% compared to the previous year[6]. - The net profit for Q1 2023 was CNY 39,622,334.78, representing a 37% increase compared to CNY 28,958,813.98 in Q1 2022[21]. - Operating profit for Q1 2023 reached CNY 41,796,167.73, up 24% from CNY 33,595,681.95 in the same period last year[21]. - The company reported a total comprehensive income of CNY 39,623,926.08 for Q1 2023, compared to CNY 28,943,664.77 in Q1 2022, indicating a 37% growth[22]. Earnings and Shareholder Returns - Basic and diluted earnings per share were both ¥0.17, representing a growth of 41.67%[6]. - Basic and diluted earnings per share for Q1 2023 were both CNY 0.17, up from CNY 0.12 in Q1 2022[22]. Cash Flow and Liquidity - The net cash flow from operating activities was ¥47,267,096.86, reflecting a 39.42% increase year-on-year[6]. - Cash flow from operating activities showed a net increase of CNY 47,267,096.86, compared to CNY 33,901,895.37 in the previous year, marking a 39% improvement[26]. - Cash and cash equivalents at the end of Q1 2023 totaled CNY 295,962,413.46, a significant increase from CNY 77,856,033.89 at the end of Q1 2022[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,815,716,832.96, an increase of 5.62% from the end of the previous year[6]. - Current assets as of March 31, 2023, totaled CNY 508,170,893.23, an increase of 16.4% from CNY 436,837,586.65 at the end of 2022[16]. - Non-current assets amounted to CNY 1,307,545,939.73, up from CNY 1,282,255,938.30 at the end of 2022[17]. - Total liabilities were CNY 685,161,016.86, compared to CNY 628,161,634.93 at the end of 2022, indicating a rise of 9.1%[18]. - Shareholders' equity attributable to the parent company was ¥1,127,636,203.30, up by 3.65% compared to the previous year[6]. - Shareholders' equity as of March 31, 2023, was CNY 1,130,555,816.10, an increase from CNY 1,090,931,890.02 at the end of 2022[18]. Borrowings and Financing - The company experienced a 38.83% increase in cash and cash equivalents, primarily due to increased bank borrowings[9]. - The company reported a significant increase of 126.94% in short-term borrowings, attributed to increased bank loans[9]. - Short-term borrowings increased significantly to CNY 173,602,852.77 from CNY 76,498,172.22 at the end of 2022, marking a rise of 127.5%[17]. - The company raised CNY 190,000,000.00 through borrowings in Q1 2023, compared to CNY 53,649,744.44 in the same period last year, indicating a substantial increase in financing activities[27]. Operating Costs and R&D - Total operating costs for Q1 2023 were CNY 122,646,292.57, down 2.3% from CNY 126,228,137.67 in Q1 2022[20]. - Operating costs included CNY 52,009,448.21 in cost of goods sold, which increased by 12.0% from CNY 46,376,303.16 in the previous year[20]. - Research and development expenses decreased by 30.57%, mainly due to reduced material costs and outsourced R&D expenses[10]. - The company incurred R&D expenses of CNY 8,275,164.89 in Q1 2023, down from CNY 11,918,349.97 in the same quarter last year, reflecting a 30% decrease[21]. Investment Activities - The total cash outflow from investing activities was CNY 29,010,001.14 in Q1 2023, down from CNY 88,883,426.86 in Q1 2022, showing a reduction of 67%[26].